In what ways can radiopharmaceuticals labeled with Tc-99m aid in cancer diagnosis?

• A. By providing therapeutic options directly
• B. By visualizing tumor locations and assessing metabolic activity
• C. By enhancing the effectiveness of chemotherapy
• D. By replacing the need for biopsies

Answer: (B)

Radiopharmaceuticals labeled with Technetium-99m are instrumental in cancer diagnosis primarily due to their ability to visualize tumor locations and assess metabolic activity. Tc-99m emits gamma rays, which can be detected by imaging equipment such as gamma cameras. This allows for the detailed visualization of physiological processes, including the uptake of radiotracers by various tissues.

In oncology, the uptake of these radiopharmaceuticals in tumor cells can indicate not only the presence of tumors but also provide insights into their aggressiveness and the metabolic state of the cancer. For example, cancers often exhibit increased metabolic activity compared to normal tissues, and this can be quantified using the gamma imaging provided by Tc-99m labeled agents.

Thus, option B accurately describes the critical role of Tc-99m in cancer diagnosis, which is through imaging and functional assessment rather than direct therapeutic intervention, enhancement of chemotherapy, or replacement of tissue biopsies. These imaging capabilities significantly improve diagnostic accuracy and contribute to better treatment planning.